← REGULATORY CHANGES
FEDERAL REGISTER · RULESeptember 1, 2023

Wholesale Distributor Verification Requirement for Saleable Returned Drug Product and Dispenser Verification Requirements When Investigating a Suspect or Illegitimate Product-Compliance Policies, Revision 1; Guidance for Industry; Availability

Document type
Rule
Agency
Health and Human Services Department
Published
September 1, 2023
Document number
2023-18899
ABSTRACT

The Food and Drug Administration (FDA or Agency) is announcing the availability of a guidance for industry entitled "Wholesale Distributor Verification Requirement for Saleable Returned Drug Product and Dispenser Verification Requirements When Investigating a Suspect or Illegitimate Product--Compliance Policies, Revision 1." This revised guidance explains that FDA intends to extend for an additional year (from November 27, 2023, to November 27, 2024), the enforcement policies described in the guidance entitled "Wholesale Distributor Verification Requirement for Saleable Returned Drug Product and Dispenser Verification Requirements When Investigating a Suspect or Illegitimate Product--Compliance Policies," published in the Federal Register on October 23, 2020 (the 2020 Compliance Policies). The 2020 Compliance Policies relate to provisions in the Federal Food, Drug, and Cosmetic Act (FD&C Act), as added by the Drug Supply Chain Security Act (DSCSA), requiring wholesale distributors to verify the product identifier prior to further distributing saleable returned product and requiring dispensers to verify the product identifier for suspect or illegitimate product in the dispenser's possession or control.

Abstract as published in the Federal Register.

PROFESSIONAL CHANGE REPORT

See the structure of SPEQ’s reviewed analysis

Explorer members can open three bounded, human-reviewed previews each month. Full relationships, analysis, and implementation implications remain protected.

Sign in free to preview →
CHECKING ACCESS

Checking your Professional access…

READ THE FULL DOCUMENT

The complete document — every provision, the docket, and the comment instructions — is published in the Federal Register. SPEQ surfaces and indexes it for reference; the authoritative text lives on federalregister.gov.

View on federalregister.gov →
PUT THIS CHANGE TO WORK
GxP HorizonWhere regulation is heading next →Decode the standardsThe requirements this rule touches →All regulatory changesBrowse the live Federal Register feed →

Document details are published in the U.S. Federal Register; SPEQ surfaces them for reference and is not affiliated with or endorsed by the FDA or the Office of the Federal Register. The authoritative text is on federalregister.gov.